| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/23/2013 | US8492351 Anti-cholesterolemic compounds and methods of use |
| 07/23/2013 | US8492350 Therapeutic agent for pain disease |
| 07/23/2013 | US8492334 Sustained intraocular delivery of drugs from biodegradable polymeric microparticles |
| 07/23/2013 | US8492331 Methods for increasing absorption of peptides, peptidomimetics and other gastrointestinal transport protein substrates |
| 07/23/2013 | US8492314 Agricultural composition with PH colour indicators |
| 07/23/2013 | US8492111 Arylalkylamine compound and process for preparing the same |
| 07/23/2013 | US8492081 Aldehyde-fixed, dried platelets with covalently attached exogenous active agent and method of making thereof |
| 07/23/2013 | US8491938 Potent inhibitory effect of zinc in combination with sulforaphane on cancer cell growth |
| 07/23/2013 | US8491935 Modified release formulations containing drug-ion exchange resin complexes |
| 07/23/2013 | US8491934 Stabilised prostaglandin composition |
| 07/23/2013 | US8491931 Treatment of faecal incontinence and other conditions with 1R, 2S-methoxamine |
| 07/23/2013 | US8491930 Pharmaceutical formulation containing ibuprofen and codeine |
| 07/23/2013 | US8491902 Medicament comprising recombinant antibody against chemokine receptor CCR4 |
| 07/23/2013 | US8491881 Conformable solvent-based bandage and coating material |
| 07/23/2013 | US8491880 Pharmaceutical formulations of biodegradable biocompatible camptothecin-polymer conjugates |
| 07/23/2013 | US8491879 Ammonium-polyurethane- and/or polycarbonate compounds |
| 07/23/2013 | US8491878 Sanitizing formulation |
| 07/23/2013 | US8491872 Cinnamic acid-based oligomers and uses thereof |
| 07/23/2013 | DE202013005637U1 Mittel mit Tocotrienol bei Verbrennungen durch Sonne, radioaktive Strahlung oder Hitze Means tocotrienol burns from the sun, nuclear radiation or heat |
| 07/23/2013 | CA2735828C Substituted-(naphthalen-1-yl)-1h-imidazoles and their use for modulating uric acid levels |
| 07/23/2013 | CA2717679C Aqueous pharmaceutical compositions containing borate-polyol complexes |
| 07/23/2013 | CA2681850C Styrenyl derivative compounds for treating ophthalmic diseases and disorders |
| 07/23/2013 | CA2681302C Proliposomal and liposomal compositions of poorly water-soluble compounds |
| 07/23/2013 | CA2664004C Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| 07/23/2013 | CA2642943C Pharmaceutical combination for the treatment and/or chemosensibilization of refractory tumors to anticancer drugs |
| 07/23/2013 | CA2635392C New pyrrolic derivatives with histone deacetylase inhibitory activity |
| 07/23/2013 | CA2630334C Use of transcriptome-modifying agents and chemotherapy or radiotherapy against cancer |
| 07/23/2013 | CA2616396C Growth hormone secretagogues |
| 07/23/2013 | CA2607106C 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline derivatives as medicaments for the treatment of infertility |
| 07/23/2013 | CA2606716C Use of pyrimidylaminobenzamide derivatives for the treatment of systematic mastocytosis |
| 07/23/2013 | CA2604078C Enteric pharmaceutical formulations of choline salt of fenofibric acid |
| 07/23/2013 | CA2599348C Indole compound and use thereof |
| 07/23/2013 | CA2596634C Isolation of atraric acid, synthesis of atraric acid derivatives, and use of atraric acid and the derivatives thereof for the treatment of benign prostatic hyperplasia, prostate carcinoma and spinobulbar muscular atrophy |
| 07/23/2013 | CA2585089C Fused pyrimidines and their use as inhibitors of pi3k |
| 07/23/2013 | CA2583967C 6-amino(aza)indane compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor |
| 07/23/2013 | CA2575033C Novel biaromatic compounds that activate ppar type receptors, and use thereof in cosmetic or pharmaceutical compositions |
| 07/23/2013 | CA2566090C Substituted n-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies |
| 07/23/2013 | CA2560226C Pharmaceutical formulations for dry powder inhalers comprising a low-dosage strength active ingredient |
| 07/23/2013 | CA2545261C Piperidine-substituted indoles- or heteroderivatives thereof |
| 07/23/2013 | CA2544574C Stable vitamin b6 derivative |
| 07/23/2013 | CA2542695C Substituted benzylaminoalkylene heterocycles |
| 07/23/2013 | CA2536518C Proteasome inhibitors and methods of using the same |
| 07/23/2013 | CA2536415C Crosslinking reagent for treating intervertebral disc disorders |
| 07/23/2013 | CA2534675C Piperazine with or-substituted phenyl group and their use as glyt1 inhibitors |
| 07/23/2013 | CA2521961C Crosslinking of low-molecular weight and high-molecular weight polysaccharides; preparation of injectable monophase hydrogels; polysaccharides and hydrogels obtained |
| 07/23/2013 | CA2493878C Parenteral formulations containing a rapamycin hydroxyester |
| 07/23/2013 | CA2471968C Immunostimulatory nucleic acids and use thereof |
| 07/23/2013 | CA2432644C Pharmaceutical composition comprising aspirintm and cs-747 |
| 07/23/2013 | CA2357950C Therapeutic phosphodiesterase inhibitors |
| 07/23/2013 | CA2250835C Novel ectoparasite saliva proteins and apparatus to collect such proteins |
| 07/23/2013 | CA2203843C Liposome-encapsulated poly iclc |
| 07/18/2013 | WO2013106855A1 Treatment of skin disease |
| 07/18/2013 | WO2013106847A1 Compounds, compositions and associated methods comprising 3-aryl quinolines |
| 07/18/2013 | WO2013106824A1 Epherin receptor targeting agents |
| 07/18/2013 | WO2013106812A1 Personalized medicine for the prediction of therapy targeting the hedgehog pathway |
| 07/18/2013 | WO2013106795A1 Substituted 4-(1h~pyrazol-4.yl)benzyl analogues as positive allosteric modulators of machr m1 receptors |
| 07/18/2013 | WO2013106792A1 Heterocyclic compounds and uses as anticancer agents. |
| 07/18/2013 | WO2013106761A2 Antimicrobial agents |
| 07/18/2013 | WO2013106756A2 Antimicrobial agents |
| 07/18/2013 | WO2013106732A1 Pharmaceutical compositions and methods for their preparation |
| 07/18/2013 | WO2013106728A1 Agents that prevent or repair skin damage |
| 07/18/2013 | WO2013106717A1 Anesthetic compounds and related methods of use |
| 07/18/2013 | WO2013106702A1 Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions |
| 07/18/2013 | WO2013106689A1 Hcv ns3 protease inhibitors |
| 07/18/2013 | WO2013106683A1 Methods of treating and preventing cancer by disrupting the binding of copper in the map kinase pathway |
| 07/18/2013 | WO2013106678A1 Tetrasubstituted benzenes |
| 07/18/2013 | WO2013106656A2 Methods of treating adverse intestinal effects of nonsteroidal anti-inflammatory drugs |
| 07/18/2013 | WO2013106646A2 Compounds and methods for the inhibition of vcb e3 ubiquitin ligase |
| 07/18/2013 | WO2013106641A1 Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors |
| 07/18/2013 | WO2013106614A1 Triazolyl-substituted pyridyl compounds useful as kinase inhibitors |
| 07/18/2013 | WO2013106612A1 Heterocyclic-substituted pyridyl compounds useful as kinase inhibitors |
| 07/18/2013 | WO2013106601A1 Pediatric oral suspension formulations of amoxicillin and clavulanate potassium and method for using same |
| 07/18/2013 | WO2013106570A1 Combination of beta-hydroxy-beta-methylbutyrate, arginine and glutamine for use in treating diabetic ulcers |
| 07/18/2013 | WO2013106565A1 Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide f2 alpha agonists |
| 07/18/2013 | WO2013106547A1 Beta-cell replication promoting compounds and methods of their use |
| 07/18/2013 | WO2013106535A1 Irak inhibitors and uses thereof |
| 07/18/2013 | WO2013106528A1 Bivalent ligands for the treatment of neurological disorders |
| 07/18/2013 | WO2013106526A1 Saxagliptin parmaceutical formulations |
| 07/18/2013 | WO2013106520A1 Hepatitis c virus inhibitors |
| 07/18/2013 | WO2013106506A1 Stabilized pharmaceutical formulations of a potent hcv inhibitor |
| 07/18/2013 | WO2013106496A1 Methods and compositions for targeting agents into and across the blood-brain barrier |
| 07/18/2013 | WO2013106494A1 Combination therapy for treating hearing and balance disorders |
| 07/18/2013 | WO2013106460A2 Compositions and methods for treating malignant astrocytomas |
| 07/18/2013 | WO2013106433A1 Cellulose derivatives for inhibiting crystallization of poorly water-soluble drugs |
| 07/18/2013 | WO2013106432A1 Benzhydrol-pyrazole derivatives having kinase inhibitory activity and uses thereof |
| 07/18/2013 | WO2013106414A1 Tryptoline derivatives having kinase inhibitory activity and uses thereof |
| 07/18/2013 | WO2013106409A1 Benzamide derivatives as modulators of the follicle stimulating hormone |
| 07/18/2013 | WO2013106358A1 Method of treating hyperlipidemia and atherosclerosis with mir-30c |
| 07/18/2013 | WO2013106349A1 Use of the aminoalkylindole jwh-073-m4 and related compounds as neutral cb1 recptor antagonists for the treatment of alcoholism, drug abuse, obesity, and obesity-related diseases |
| 07/18/2013 | WO2013106344A1 2 '-c-methyl nucleosides containing a cyclic phosphate diester of 1, 3-propanediol (2-oxo-[1, 3, 2]-dioxaphosphorinane) at position 5' |
| 07/18/2013 | WO2013106328A1 Tetrasubstituted benzenes for treatment of early onset alzheimer's disease |
| 07/18/2013 | WO2013106238A1 Leukotriene b4 antagonist compound |
| 07/18/2013 | WO2013106226A2 Methods of treating or preventing insulin resistance and associated diseases and conditions |
| 07/18/2013 | WO2013106216A1 Antimicrobial product and method |
| 07/18/2013 | WO2013106175A1 Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof |
| 07/18/2013 | WO2013106108A2 Cartridge and method for increasing myocardial function |
| 07/18/2013 | WO2013106084A1 Methods and drug products for treating alzheimer's disease |
| 07/18/2013 | WO2013106029A1 Taxane and abeo-taxane analogs |
| 07/18/2013 | WO2013105985A1 Small molecule inhibitors of rad51 recombinase and methods thereof |
| 07/18/2013 | WO2013105924A2 Oral care compositions |